Compare · LIPO vs NVO
LIPO vs NVO
Side-by-side comparison of Lipella Pharmaceuticals Inc. (LIPO) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LIPO and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO carries a market cap of $187.53B.
- Over the past year, LIPO is down 18.1% and NVO is down 41.7% - LIPO leads by 23.5 points.
- NVO has hit the wire 11 times in the past 4 weeks while LIPO has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 0 for LIPO).
- Company
- Lipella Pharmaceuticals Inc.
- Novo Nordisk A/S
- Price
- $2.30-15.44%
- $42.01-2.10%
- Market cap
- -
- $187.53B
- 1M return
- +0.00%
- -5.38%
- 1Y return
- -18.15%
- -41.69%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2022
- News (4w)
- 0
- 11
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest LIPO
- Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Financial Statements and Exhibits
- Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update
- SEC Form 10-Q filed by Lipella Pharmaceuticals Inc.
- Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update
- Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update
- Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Lipella Pharmaceuticals Announces Positive Final Results from Phase 2a Study of LP-10 in Oral Lichen Planus
- Lipella Pharmaceuticals to Present at Zacks SCR Life Sciences Virtual Investor Forum and Report Final Phase 2a Results in Oral Lichen Planus
- SEC Form 10-Q filed by Lipella Pharmaceuticals Inc.
- Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates